Otonomy Provides Update on Clinical Trials and Development Programs
- Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021
- Results from Phase 1/2 trial of OTO-313 in tinnitus expected in
- Results from Phase 1/2 trial of OTO-413 in hearing loss expected in fourth quarter of 2020
- Current capital funds operations through all clinical trial readouts
Conference call and webcast today at
“We have been able to mitigate the impact of the COVID-19 pandemic on our clinical trials by taking steps to ensure the integrity of data collection from enrolled patients and supporting the increasing number of sites able to reinitiate recruitment of new patients,” said
Otonomy Program Updates
- OTIVIDEX Phase 3 clinical trial in Ménière’s disease: patient enrollment is ongoing with results expected in the first quarter of 2021. This trial is being conducted at approximately 60 trial sites dispersed across different regions of
the United Statesand multiple countries in Europe. We believe there is minimal impact of COVID-19 on the integrity of efficacy data being collected because patients report their vertigo episodes via a daily telephone diary and compliance remains high. New patient enrollment was impacted beginning in March due to quarantine restrictions but we are now seeing renewed activity across numerous sites in multiple countries. We expect to complete patient enrollment during the third quarter of 2020 and announce results in the first quarter of 2021.
- OTO-313 Phase 1/2 clinical trial in tinnitus: results from exploratory efficacy cohort expected in
July 2020. We have completed enrollment in the exploratory efficacy cohort of this randomized, double-blind, placebo-controlled trial and are currently conducting study completion activities. This cohort enrolled 35 patients with at least moderate tinnitus severity assessed during a two-week lead-in period using the Tinnitus Functional Index (TFI), a clinically-validated tinnitus questionnaire. Patients were randomized 1:1 to a single intratympanic injection of OTO-313 (sustained exposure formulation of the NMDA receptor antagonist gacyclidine) or placebo, and followed for eight weeks. In addition to scoring the severity of their tinnitus at regular intervals using the TFI, patients also reported their tinnitus loudness and annoyance using a daily telephone diary during the follow-up period. While not powered for statistical significance, we believe this patient number and study design will be sufficient to assess a clinical signal with OTO-313 treatment and inform next steps for the program. We expect to announce study results in July.
- OTO-413 Phase 1/2 clinical trial in hearing loss: patient enrollment is ongoing with results expected in the fourth quarter of 2020. This is an ascending single dose safety and exploratory efficacy study for OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor (BDNF). We have successfully escalated through three dose levels totaling 24 patients and recently initiated enrollment for the high dose cohort. We expect to enroll approximately 16 patients in this cohort, randomized 3:1 for a single intratympanic injection of OTO-413 or placebo. Patients enrolled in this trial have a speech-in-noise hearing deficit measured at baseline and can have normal up to moderately-severe hearing loss by conventional testing. Following treatment, patients undergo repeated testing for safety and exploratory efficacy over 3 months. We expect to announce results from this trial in the fourth quarter of 2020.
- GJB2 gene therapy program: preclinical results support selection of product candidate.
Otonomyand Applied Genetic Technologies Corporation (AGTC) are collaborating to co-develop and co-commercialize an AAV-based gene therapy to restore hearing in patients with hearing loss caused by a mutation in the gap junction beta-2 (GJB2) gene -- the most common cause of congenital hearing loss. Preclinical results presented at the American Society of Gene & Cell Therapy(ASGCT) meeting in May 2020demonstrated that a gene of interest can be expressed in support cells of the cochlea, which are the relevant target cells for treating GJB2 deficiency, using novel and proprietary AAV capsids. Also, consistent gene expression can be observed in these cells for at least 12 weeks following a single local administration. These results support the selection of a product candidate for further development.
- OTO-510: preclinical data presented for novel and proprietary class of otoprotectant agents. Cisplatin is a potent chemotherapeutic agent that is widely used to treat a variety of cancers in adults and children, however, it is commonly associated with severe adverse effects including cisplatin-induced hearing loss (CIHL).
Otonomyhas presented preclinical results demonstrating varying degrees of otoprotection against CIHL for several classes of therapeutic agents. In particular, a novel class of agents that potently binds to cisplatin demonstrated greater otoprotection than anti-oxidant and anti-apoptotic molecules, and increased potency relative to other cisplatin-binding molecules currently in development.
- OTO-6XX: preclinical development ongoing for regenerative hearing loss program.
Otonomyhas demonstrated regeneration of hair cells in a preclinical proof-of-concept model using a class of small molecules formulated for sustained-exposure local delivery, and has selected a lead compound for development. The OTO-6XX program is targeting hair cell regeneration for the treatment of severe hearing loss.
- OTIPRIO® Co-Promotion Agreement completed with ALK-Abelló, Inc. (ALK).
Otonomyrecently entered a co-promotion agreement that provides ALK with an exclusive right to promote OTIPRIO for acute otitis externa (AOE) to office-based health care professionals in the United Statesincluding ear, nose and throat (ENT) physicians, pediatricians and primary care physicians. During the multi-year agreement, Otonomywill receive co-promotion fees and reimbursement of a proportion of product support costs while also retaining a share of adjusted gross profits from the sale of OTIPRIO for use in AOE.
- Financial Guidance:
- 2020 Operating Expenses:
Otonomycontinues to expect that non-GAAP operating expenses will be in the range of $35-$38 million, and GAAP operating expenses will be in the range of $45-$48 million.
- Cash Runway:
Otonomyexpects that its current cash, cash equivalents, and short-term investments will be sufficient to fund company operations to mid-2021, through readouts for our three ongoing clinical trials.
- 2020 Operating Expenses:
Webcast and Conference Call
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the future financial or operating performance of
Source: Otonomy, Inc.